208 related articles for article (PubMed ID: 20028770)
1. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
Galimberti F; Thompson SL; Liu X; Li H; Memoli V; Green SR; DiRenzo J; Greninger P; Sharma SV; Settleman J; Compton DA; Dmitrovsky E
Clin Cancer Res; 2010 Jan; 16(1):109-20. PubMed ID: 20028770
[TBL] [Abstract][Full Text] [Related]
2. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
[TBL] [Abstract][Full Text] [Related]
3. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
Kawakami M; Mustachio LM; Rodriguez-Canales J; Mino B; Roszik J; Tong P; Wang J; Lee JJ; Myung JH; Heymach JV; Johnson FM; Hong S; Zheng L; Hu S; Villalobos PA; Behrens C; Wistuba I; Freemantle S; Liu X; Dmitrovsky E
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376145
[TBL] [Abstract][Full Text] [Related]
4. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.
Hu S; Danilov AV; Godek K; Orr B; Tafe LJ; Rodriguez-Canales J; Behrens C; Mino B; Moran CA; Memoli VA; Mustachio LM; Galimberti F; Ravi S; DeCastro A; Lu Y; Sekula D; Andrew AS; Wistuba II; Freemantle S; Compton DA; Dmitrovsky E
Cancer Res; 2015 May; 75(10):2029-38. PubMed ID: 25808870
[TBL] [Abstract][Full Text] [Related]
5. Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.
Hu S; Lu Y; Orr B; Godek K; Mustachio LM; Kawakami M; Sekula D; Compton DA; Freemantle S; Dmitrovsky E
Mol Cancer Ther; 2015 Nov; 14(11):2576-85. PubMed ID: 26304236
[TBL] [Abstract][Full Text] [Related]
6. Targeting low molecular weight cyclin E (LMW-E) in breast cancer.
Nanos-Webb A; Jabbour NA; Multani AS; Wingate H; Oumata N; Galons H; Joseph B; Meijer L; Hunt KK; Keyomarsi K
Breast Cancer Res Treat; 2012 Apr; 132(2):575-88. PubMed ID: 21695458
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.
Josefsberg Ben-Yehoshua L; Beider K; Shimoni A; Ostrovsky O; Samookh M; Peled A; Nagler A
PLoS One; 2012; 7(4):e33856. PubMed ID: 22558078
[TBL] [Abstract][Full Text] [Related]
8. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
9. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.
Kawakami M; Mustachio LM; Chen Y; Chen Z; Liu X; Wei CH; Roszik J; Kittai AS; Danilov AV; Zhang X; Fang B; Wang J; Heymach JV; Tyutyunyk-Massey L; Freemantle SJ; Kurie JM; Liu X; Dmitrovsky E
Mol Cancer Ther; 2021 Mar; 20(3):477-489. PubMed ID: 33277443
[TBL] [Abstract][Full Text] [Related]
10. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents.
Fleming IN; Hogben M; Frame S; McClue SJ; Green SR
Clin Cancer Res; 2008 Jul; 14(13):4326-35. PubMed ID: 18594016
[TBL] [Abstract][Full Text] [Related]
12. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
13. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
14. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
Iurisci I; Filipski E; Reinhardt J; Bach S; Gianella-Borradori A; Iacobelli S; Meijer L; Lévi F
Cancer Res; 2006 Nov; 66(22):10720-8. PubMed ID: 17108108
[TBL] [Abstract][Full Text] [Related]
15. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance.
Khalil HS; Mitev V; Vlaykova T; Cavicchi L; Zhelev N
J Biotechnol; 2015 May; 202():40-9. PubMed ID: 25747275
[TBL] [Abstract][Full Text] [Related]
16. Seliciclib in malignancies.
Aldoss IT; Tashi T; Ganti AK
Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
[TBL] [Abstract][Full Text] [Related]
17. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.
Akli S; Van Pelt CS; Bui T; Meijer L; Keyomarsi K
Cancer Res; 2011 May; 71(9):3377-86. PubMed ID: 21385896
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma.
Cheng CK; Gustafson WC; Charron E; Houseman BT; Zunder E; Goga A; Gray NS; Pollok B; Oakes SA; James CD; Shokat KM; Weiss WA; Fan QW
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12722-7. PubMed ID: 22802621
[TBL] [Abstract][Full Text] [Related]
19. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
[TBL] [Abstract][Full Text] [Related]
20. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
